Appreciate the Musella Foundation / @VirtualTrials further highlighting the Phase 1 results for oral gallium maltolate in recurrent #GBM: virtualtrials.org/newsarticl… Strong safety profile OS ~16 months, with long-term survivors >30 months. Early data—but highlights the value of continuing innovation in this space. Encouraging early signal in a difficult disease. #glioblastoma #neurooncology #braincancer #clinicaltrials

The Problem with Conventional MRI. There's up to a 40% disagreement in post-treatment MRI interpretation—why? Conventional MRI remains the foundation of brain tumor imaging—but it has limitations. Post-treatment changes, inflammation, and blood products can all mimic tumor progression. This leads to variability in interpretation and uncertainty in clinical decision-making. Advanced imaging isn’t about replacing MRI—it’s about making it more reliable, quantitative, and actionable. At Imaging Biometrics, our focus is simple: ➡️ Reduce ambiguity ➡️ Standardize results ➡️ Support confident clinical decisions

Imaging interpretation turnaround times more than double over a decade radiologybusiness.com/topics… MR is up 256%. CT is up 318%. Radiologists are maxed out. @ImgBiometrics delivers fully automated quantitative maps — objective, reproducible, and available within seconds of acquisition. As radiology faces soaring volume and shrinking workforce capacity, IB provides what the system can’t: speed, standardization, and true scalability. If the specialty has hit its limit, the answer isn’t more hours — it’s automation that removes variability and accelerates interpretation.

Congratulations to Dr. Mona Al‑Gizawiy of the Medical College of Wisconsin on securing a new NIH R01 award—and to announce our role as a sub‑award recipient on this important project. This five‑year, $3M grant will accelerate the understanding of gallium maltolate (GaM), a promising oral therapy targeting some of the most aggressive pediatric brain cancers. Under Dr. Al‑Gizawiy’s leadership, the pre-clinical project will advance the combination of GaM with radiation therapy, building on early evidence that GaM can enhance treatment effectiveness. IB will support this work with our FDA‑cleared quantitative MR imaging platform—including our advanced Fractional Tumor Burden (FTB) maps—which delivers standardized, highly sensitive measures of tumor response. This capability is essential for evaluating emerging therapies and represents a key differentiator in the neuro‑oncology imaging market. “IB’s quantitative imaging gives us an early and reliable window into how tumors respond to treatment—something conventional scans simply can’t match,” said Dr. Al‑Gizawiy. IB packages pre-clinical imaging workflows to create a unified imaging ecosystem that strengthens our position across research and clinical markets. This initiative supports long‑term growth by expanding IB’s footprint in translational research and multi‑site trials. #PediatricBrainCancer #ChildhoodCancerResearch #PediatricOncology #BrainTumorResearch #DIPG #Glioblastoma #ATRT #HighGradeGlioma #ftbmaps

Everyone knows manual normalization of MR DSC perfusion is the Achilles’ heel of neuro MRI—subjective, inconsistent, and impossible to reproduce across scanners or sites. Yet the industry still pretends it’s “good enough.” It isn’t. @ImgBiometrics eliminated this problem years ago. Our fully quantitative, harmonized imaging makes MRI exams truly comparable anywhere. If decentralized neuro imaging is the goal, manual normalization is the roadblock—and IB is the way past it. Shift toward imaging outside the hospital could save billions radiologybusiness.com/topics…

The absolute scenes when that 4th goal went in for these Scottish fans 👏🤣🤣🤣

Imaging Biometrics’ FTB technology is now part of a Phase 2 GBM trial at MD Anderson/Cooper University! Proud to support innovations that may reshape GBM care. proactiveinvestors.co.uk/com…

$IBAI Imaging Biometrics technology adopted in trial aiming to reshape GBM treatment strategy tinyurl.com/22gpxomu @ImgBiometrics $5Y1 $IQAIF #IBAI #5Y1 #IQAIF

Amazing skills 🙏🏻 Lest We Forget.

Good grief. John Lewis appear to have completely ignored the Britain hating DEI lunatics. Well done John Lewis. What a lovely advert.

Mike Rendall, Chief Technology Officer at AFC Energy and Managing Director at @HYAMTEC, has become the inaugural Chair of UK Ammonia Alliance – a coalition supercharging the growth of low-carbon ammonia in the UK ⚡ Further details: londonstockexchange.com/news… #UKAmmonia #NetZero

🚀 October Highlights • Dr. Kathleen Schmainda opens St. Jude’s Pediatric Neuro-Oncologic Imaging Course 🎓 • FDA-cleared QSMetric™ now available—quantifying iron, hemorrhage & neuroinflammation for MS, DBS, CCM & glioma 🧲 • 🧠 Join Dr. Max Krucoff’s Nov 19 webinar on advanced imaging for biopsy & LITT in recurrent brain tumors • 🤝 IB Vivan Therapeutics partner to advance Gallium Maltolate for new cancer indications mailchi.mp/imagingbiometrics…

Don't miss our next webinar! November 19- Imaging Techniques for Biopsy Targeting and LITT Ablation-events.teams.microsoft.com/e…

#IBAI a very interesting find by maximillion69 over on LSE who has highlighted the post by @hub71ad via linkedin.com/posts/hub71ad_h… So who are hub71, take a read hub71.com Very interesting!!

Visit @PrismClinical at #2025CNS Booth 457 to learn how @ImgBiometrics' FTB maps are transforming #Neurosurgery. Integrated with Prism’s suite, IB’s automated mapping improves surgical planning, biopsy targeting & treatment decisions—backed by recent clinical studies. @CNS_Update

We’re proud to share that @ImgBiometrics' co-founder, Professor Kathleen Schmainda, will be opening the @StJudeResearch seminar on Advanced Neuroimaging in Pediatric Brain Tumors. Her pioneering work continues to shape the future of precision imaging in oncology. Oct 30 - Nov 2 stjude.cloud-cme.com/course/… #Neuroimaging #PediatricCancer #BrainTumors #ImagingBiometrics #StJude

#IBAI displayed quote was 0.55p / 0.70p but you could sell 500k at 0.645p. Finally they have ticked up!

When the presentation title is longer than your MRI scan time..."MR Perfusion: Improving Reliability with Standardized MRP, Digital Reference Objects, and a Personalized Plan Based on the Patient's Treatment History" Catch Prof Kathleen Schmainda's talk Sunday at 10:30 at the #ASFNR2025 meeting, and learn about @ImgBiometrics #FTBmaps @theASFNR @NeuroOnc @TheASNR @AlMusella @theABTA @NBTStweets

🚀 We’ve launched our new website! Explore Imaging Biometrics’ advanced brain tumor imaging solutions, clinical evidence, and resources for neuro-oncology. 👉 imagingbiometrics.com

$PHE Powerhouse Energy boosts hydrogen output in waste-to-fuel trials tinyurl.com/ymr7g96y @powerhouseeg $BT81 #PHE #BT81